Abstract
Background Synaptic loss is a prominent and early feature of many neurodegenerative diseases.
Objectives We tested the hypothesis that synaptic density is reduced in the primary tauopathies of progressive supranuclear palsy (PSP-Richardson’s syndrome) and amyloid-negative corticobasal syndrome (CBS).
Methods Forty four participants (15 CBS, 14 PSP, and 15 age-/sex-/education-matched controls) underwent positron emission tomography (PET) with the radioligand [11C]UCB-J, which binds to synaptic vesicle glycoprotein 2A (SV2A), a marker of synaptic density; participants also had 3T magnetic resonance imaging and clinical and neuropsychological assessment.
Results Nine CBS patients had negative amyloid biomarkers determined by [11C]PiB PET and hence were deemed likely to have corticobasal degeneration (CBD). Patients with PSP-Richardson’s syndrome and amyloid-negative CBS were impaired in executive, memory and visuospatial tasks. [11C]UCB-J binding was reduced across frontal, temporal, parietal, and occipital lobes, cingulate, hippocampus, insula, amygdala and subcortical structures in both PSP and CBD patients compared to controls (p<0.01), with median reductions up to 50%, consistent with post mortem data. Reductions of 20-30% were widespread even in the areas of the brain with minimal atrophy. There was a negative correlation between global [11C]UCB-J binding and the PSP and CBD rating scales (R= −0.61 p<0.002, R= −0.72 p<0.001, respectively) and a positive correlation with the revised Addenbrookes Cognitive Examination (R=0.52, p=0.01).
Conclusions We confirm severe synaptic loss in PSP and CBD in proportion to disease severity, providing critical insight into the pathophysiology of primary degenerative tauopathies. [11C]UCB-J may facilitate treatment strategies for disease-modification, synaptic maintenance or restoration.
Competing Interest Statement
NH is funded by the Association of British Neurologists - Patrick Berthoud Charitable Trust. PSJ has no financial disclosures to report. GS has no financial disclosures to report. JKW has no financial disclosures to report. YTH has no financial disclosures to report. TDF has no financial disclosures to report. RM has no financial disclosures to report. SMS has no financial disclosures to report. IB has no financial disclosures to report. FIA has no financial disclosures to report. JBR serves as an associate editor to Brain, and is a non-remunerated trustee of the Guarantors of Brain and the PSP Association (UK). He provides consultancy to Asceneuron, Biogen and UCB and has research grants from AZ-Medimmune, Janssen and Lilly as industry partners in the Dementias Platform UK. JOB provides consultancy to Axon, TauRx and Eisai and has research grant support from Alliance Medical and Merck.
Funding Statement
The study was funded by the Cambridge University Centre for Parkinson-Plus; the National Institute for Health Research Cambridge Biomedical Research Centre (SUAG/004 RG91365 JBR); the Wellcome Trust (103838) and the Association of British Neurologists, Patrick Berthoud Charitable Trust (RG99368).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosures/conflict of interest:s The authors do not have any competing interest pertaining to the manuscript.
Funding: The study was funded by the Cambridge University Centre for Parkinson-Plus; the National Institute for Health Research Cambridge Biomedical Research Centre (SUAG/004 RG91365 JBR); the Wellcome Trust (103838) and the Association of British Neurologists, Patrick Berthoud Charitable Trust (RG99368). MP is supported by Cambridge Trust Vice-Chancellor’s Award & Sidney Sussex College Scholarship. FHH is supported by a Cambridge Trust Vice-Chancellor’s Award & Fitzwilliam College scholarship.
Data Availability
The derived data that support the findings of this study are available from the corresponding author, upon reasonable request for academic (non-commercial) purposes.
